Sentinel <scp>node‐assisted</scp> neck dissection in advanced oral squamous cell carcinoma—A new protocol for staging and treatment

Bark, Rusana; Kolev, Aeneas; Elliot, Alexandra; Piersiala, Krzysztof; Näsman, Anders; Grybäck, Per; Georén, Susanna Kumlien; Wendt, Malin; Cardell, Lars Olaf; Margolin, Gregori; Marklund, Linda

doi:10.1002/cam4.5966

Cited by 3 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…New diagnostic tools have been increasingly available for accurate HNC diagnosis. The implementation of sentinel node biopsies in Sweden could also have contributed to identifying more contra- or bilateral metastases [ 46 ]. Moreover, the use of Positron Emission Tomography with 2-deoxy-2-[fluorine-18] fluoro- D-glucose integrated with Computed Tomography, FDG-PET/CT has improved the detection of regional and distant metastases [ 47 , 48 ].…”

Section: Discussionmentioning

confidence: 99%

Six-month mortality has decreased for patients with curative treatment intent for head and neck cancer in Sweden

Talani,

Högmo,

Laurell

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Background In general, survival outcomes for patients with Head and Neck Cancer (HNC) has improved over recent decades. However, mortality within six months after diagnosis for curative patients remains at approximately 5%. The aim of this study was to identify risk factors for early death among patients with curative treatment, and furthermore, to analyze whether the risk of early death changed over recent years. Material and method This real-world, population-based, nationwide study from the Swedish Head and Neck Cancer Register (SweHNCR) included all patients ≥18 years diagnosed with HNC with a curative treatment intent at the multidisciplinary tumor board from 2008 to 2020. A total of 16,786 patients were included. Results During the study period a total of 618 (3.7%) patients with curative-intended treatment died within six months of diagnosis. Patients diagnosed between 2008 and 2012 had a six-month mortality rate of 4.7% compared to 2.5% for patients diagnosed between 2017 and 2020, indicating a risk reduction of 53% (p <0.001) for death within six months. The mean time to radiation therapy from diagnosis in the 2008–2012 cohort was 38 days, compared to 22 days for the 2017–2020 cohort, (p <0.001). The mean time to surgery from diagnosis was 22 days in 2008–2012, compared to 15 days for the 2017–2020 cohort, (p <0.001). Females had a 20% lower risk of dying within six months compared to males (p = 0.013). For every year older the patient was at diagnosis, a 4.8% (p <0.001) higher risk of dying within six months was observed. Patients with a WHO score of 1 had approximately 2.4-times greater risk of early death compared to WHO 0 patients (p <0.001). The risk of early death among WHO 4 patients was almost 28 times higher than for WHO 0 patients (p <0.001). Patients with a hypopharyngeal tumor site had a 2.5-fold higher risk of dying within six months from diagnosis compared to oropharyngeal tumor patients (p <0.001). Conclusions We found that the risk of early death decreased significantly from 2008 to 2020. During this period, the mean time to the start of treatment was significantly reduced both for surgery and oncological treatment regimes. Among patients with a curative treatment intention, increased risk of early death was associated with male sex, older age, advanced disease, increased WHO score, and a hypopharyngeal tumor site.

show abstract

Section: Discussionmentioning

confidence: 99%

Six-month mortality has decreased for patients with curative treatment intent for head and neck cancer in Sweden

Talani,

Högmo,

Laurell

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

Sentinel node‐assisted neck dissection in advanced oral squamous cell carcinoma—A new protocol for staging and treatment

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

A novel near-infrared EGFR targeting probe for metastatic lymph node imaging in preclinical mouse models

Xie,

Li,

Shi

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

For the treatment of patients with oral squamous cell carcinoma (OSCC), the imaging of cervical lymph nodes and the evaluation of metastastic progression are of great significance. In recent years, the development of new non-radioactive lymph node tracers has been an area of intense research. Here, we report the synthesis, good biocompatibility, and in vivo evaluation of a new small molecule near-infrared (NIR) fluorescence probe by the conjugation of Lapatinib to S0456 (LP-S). We show that like Lapatinib, LP-S binds to the epidermal growth factor receptor (EGFR) resulting in high quality fluorescence imaging of metastatic lymph nodes in OSCC mouse models. After local injection of LP-S into the tumor, the lymphatic drainage pathway and lymph nodes can be clearly identified by NIR fluorescence imaging. Further, the LP-S probe shows higher contrast and longer retention in metastatic lymph nodes, allowing them to be differentiated from normal lymph nodes, and affording a new choice for fluorescence-guided surgery. Graphical abstract

show abstract

Sentinel node‐assisted neck dissection in advanced oral squamous cell carcinoma—A new protocol for staging and treatment

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 3 publications

References 37 publications

Six-month mortality has decreased for patients with curative treatment intent for head and neck cancer in Sweden

Six-month mortality has decreased for patients with curative treatment intent for head and neck cancer in Sweden

Sentinel node‐assisted neck dissection in advanced oral squamous cell carcinoma—A new protocol for staging and treatment

A novel near-infrared EGFR targeting probe for metastatic lymph node imaging in preclinical mouse models

Contact Info

Product

Resources

About